US20110142989A1 - Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP - Google Patents
Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP Download PDFInfo
- Publication number
- US20110142989A1 US20110142989A1 US12/836,876 US83687610A US2011142989A1 US 20110142989 A1 US20110142989 A1 US 20110142989A1 US 83687610 A US83687610 A US 83687610A US 2011142989 A1 US2011142989 A1 US 2011142989A1
- Authority
- US
- United States
- Prior art keywords
- casein
- enzyme
- vpp
- ipp
- hydrolysed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 118
- 235000021240 caseins Nutrition 0.000 title claims abstract description 113
- 239000005018 casein Substances 0.000 title claims abstract description 111
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 title claims abstract 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 78
- 108090000790 Enzymes Proteins 0.000 claims abstract description 78
- 239000000758 substrate Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 25
- 241000228212 Aspergillus Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 11
- 238000000855 fermentation Methods 0.000 claims description 46
- 230000004151 fermentation Effects 0.000 claims description 46
- 102000035195 Peptidases Human genes 0.000 claims description 31
- 108091005804 Peptidases Proteins 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 27
- 235000019833 protease Nutrition 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 18
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 9
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 9
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 9
- 240000006439 Aspergillus oryzae Species 0.000 claims description 5
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 5
- 108010059378 Endopeptidases Proteins 0.000 claims description 4
- 102000005593 Endopeptidases Human genes 0.000 claims description 4
- 102000018389 Exopeptidases Human genes 0.000 claims description 4
- 108010091443 Exopeptidases Proteins 0.000 claims description 4
- 101710135670 Putative Xaa-Pro dipeptidyl-peptidase Proteins 0.000 claims description 4
- 101710143531 Xaa-Pro dipeptidyl-peptidase Proteins 0.000 claims description 4
- 235000019658 bitter taste Nutrition 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 description 116
- 108010076119 Caseins Proteins 0.000 description 116
- 229940088598 enzyme Drugs 0.000 description 62
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 62
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 60
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 60
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 58
- UOJPTUWXHXNLDB-UHFFFAOYSA-N linaloyl diphosphate Chemical compound CC(C)=CCCC(C)(C=C)OP(O)(=O)OP(O)(O)=O UOJPTUWXHXNLDB-UHFFFAOYSA-N 0.000 description 41
- 239000000047 product Substances 0.000 description 41
- 101001003687 Homo sapiens Lipoma-preferred partner Proteins 0.000 description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 30
- 235000013336 milk Nutrition 0.000 description 27
- 239000008267 milk Substances 0.000 description 27
- 210000004080 milk Anatomy 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 238000011534 incubation Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 230000007062 hydrolysis Effects 0.000 description 16
- 238000006460 hydrolysis reaction Methods 0.000 description 16
- 235000015140 cultured milk Nutrition 0.000 description 15
- 229960000448 lactic acid Drugs 0.000 description 15
- 235000020183 skimmed milk Nutrition 0.000 description 15
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 235000021247 β-casein Nutrition 0.000 description 11
- 239000004365 Protease Substances 0.000 description 9
- 235000013365 dairy product Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000013618 yogurt Nutrition 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 108010007119 flavourzyme Proteins 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 235000008924 yoghurt drink Nutrition 0.000 description 5
- 235000021246 κ-casein Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 108010033929 calcium caseinate Proteins 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 235000014048 cultured milk product Nutrition 0.000 description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- -1 lactate ion Chemical class 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 235000020122 reconstituted milk Nutrition 0.000 description 4
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011942 biocatalyst Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000020124 milk-based beverage Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 229940021722 caseins Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- ALNAGNSGFQXERV-INZIHYEWSA-N 2-aminoacetic acid;4-nitroaniline;(2s)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1.NC1=CC=C([N+]([O-])=O)C=C1 ALNAGNSGFQXERV-INZIHYEWSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- XOEMATDHVZOBSG-UHFFFAOYSA-N azafenidin Chemical group C1=C(OCC#C)C(Cl)=CC(Cl)=C1N1C(=O)N2CCCCC2=N1 XOEMATDHVZOBSG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229940093932 potassium hydroxide Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
- A23C9/1209—Proteolytic or milk coagulating enzymes, e.g. trypsine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/913—Aspergillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/913—Aspergillus
- Y10S435/918—Aspergillus oryzae
Definitions
- the invention relates to a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP.
- the invention further relates to a process for the preparation of such hydrolysed casein product and to food products produced using the hydrolysed casein product.
- Hypertension or high blood pressure is considered to be one of the main risk factors for Cardio Vascular Diseases (CVD).
- CVD Cardio Vascular Diseases
- One of the mechanisms which regulates blood pressure is the renin-angiotensin system. This is a cascade of reactions leading to the formation of angiotensin II, which has a strong vasoconstrictive and hence blood pressure increasing effect. Inhibition of one of the key enzymes in this cascade:
- Angiotensin I Converting Enzyme reduces formation of angiotensin II and thus has a blood pressure lowering effect.
- Long term human intervention studies have shown regular intake of low amounts of ACE inhibitors reduces CVD by 25% (Gerstein et al. (2000), The Lancet 355, 253-259).
- a commercially available fermented milk product which claims to be “suitable for those with mild hypertension” is Calpis sour milk, fermented with Lactobacillus helveticus and Saccharomyces cervisiae, produced by Calpis Food Industry, Japan.
- Both fermented milk products are fermented with Lactobacillus helveticus ( Lb. helveticus ) strains.
- the products contain bioactive peptides (VPP and IPP) responsible for in vitro ACE inhibition, which are produced by proteolysis of caseins.
- VPP and IPP bioactive peptides responsible for in vitro ACE inhibition, which are produced by proteolysis of caseins.
- Lb. helveticus is one of the most efficient proteolytic Lactobacillus species.
- caseins by the proteolytic system of lactic acid bacteria can be divided into three stages. Initially breakdown of casein is performed by extracellular proteinases, followed by the uptake of di/tri peptides and oligopeptides (4 to 12 amino acidic residues) using specific uptake mechanisms. In the last stage, peptides are further degraded by intracellular peptidases, yielding small peptides and amino acids for bacterial growth.
- This complicated proteolytic system of lactic acid bacteria is described in Kunji et al., (1996), Molecular Microbiology 27, 1107-1118. A review on the intracellular peptidase system can be found in Christensen et al., (1999), Molecular Microbiology 76, 217-246.
- EP-A-1016709 it is desired to produce fermented milk with higher content of the lactotripeptides compared to the content of the lactic acid generated in the fermented milk. It provides a Lactobacillus helveticus strain CM4 that in fermentation gives 30-50 ⁇ g of tripeptides Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) per 0.01 g of DL-lactic acid.
- VPP Val-Pro-Pro
- IPP Ile-Pro-Pro
- WO 01/034828 discloses a process for producing tripeptides VPP and/or IPP starting from casein using enzymes.
- casein is treated with proteinase to produce an intermediate peptide and then digesting the intermediate peptide with peptidase.
- the best results in WO 01/034828 are shown in example 2 where casein hydrolysed with papain and Lactobacillus helveticus derived peptidase gives a VPP yield is 25% and the IPP yield 97.5%, based on beta-casein. Assuming an average content of 30 wt. % beta-casein and 15 wt.
- the yield of IPP yield of 97.5% based on beta-casein corresponds to a yield of 54% based on beta-casein and kappa casein together, as used herein. In the other examples lower yields are reported.
- Another object is to provide a food product having a good taste.
- One or more of these objects are attained according to the invention, which provides a process for the preparation of a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP, wherein a substrate comprising casein or casein fragments is subjected to enzyme treatment wherein the enzyme is derived from Aspergillus, wherein the enzyme concentration is 2-10 wt. % based on casein and that the enzyme has a high proteolytic activity.
- the enzyme comprises endopeptidases, exopeptidases and proteinases.
- the invention further relates to a hydrolysed casein food product comprising 200 ⁇ M or more of IPPeq, preferably 400 ⁇ M or more of IPPeq as defined hereafter.
- a hydrolysed casein food product comprising 200 ⁇ M or more of IPPeq, preferably 400 ⁇ M or more of IPPeq as defined hereafter.
- the hydrolysed casein food product has a non-bitter taste.
- Enzyme is herein understood to also include a mixture of more than one enzyme.
- Casein is herein understood to include all types of casein, including alpha casein, beta casein, gamma casein and kappa casein. It is noted that the fragment IPP occurs in both beta- and kappa-casein. The fragments VPP and LPP both occur once in beta casein.
- Substrate herein means any material containing casein and/or casein fragments, when used as the material treated with the enzyme.
- Proteases are herein any of a group of enzymes that cleave peptide bonds of proteins (polypeptides) resulting in shorter peptides and amino acids.
- Exopeptidase is herein defined as an enzyme that acts only near the ends of polypeptide chains. Based on their site of action at the N or C terminus they are classified as amino- or carboxypeptidases, respectively.
- Endopeptidase is herein defined as an enzyme that acts preferentially at the peptide bonds in the inner regions of the polypeptide chains away from the N and C termini.
- High proteolytic activity of the enzyme is herein defined as a proteolytic activity corresponding to a degree of hydrolysis of 20% or higher as measured in accordance with the experimental part of this specification, at a hydrolysis time of 6 hours and en enzyme concentration of 5 wt. % based on casein.
- the enzyme has a X-Prolyl dipeptidyl aminopeptidase activity or 400 U/kg or more, more preferably 700 U/kg or more, even more preferably 1200 u/kg or more.
- VPP The peptide Val-Pro-Pro
- IPP the peptide Ile-Pro-Pro
- LPP Leu-Pro-Pro
- Lactobacillus is herein abbreviated as Lb.
- Tripeptides VPP, IPP and/or LPP as defined herein include VPP, IPP, LPP and mixtures of these peptides.
- the total molar amount of tripeptides VPP, IPP and/or LPP in mixtures are herein calculated by addition of molar amounts of the tripeptides in the mixture.
- the process according to the invention produces the active tripeptides VPP, IPP, and LPP, which have a different activity.
- the IC 50 the concentration which results in 50% inhibition of the ACE activity is 5 ⁇ M for IPP and 9 ⁇ M for VPP (Kohmura, M. et al. (1990), Agricultrural and Biochemical Chemistry, 54, 835-836 and Nakamura, Y et al. (1995), J. Dairy Sci. 78, 1253-1257).
- the IC 50 ACE inhibition value for LPP is 9.6 ⁇ M (Maruyama S. et al. (1989), Agricultural and Biochemical Chemistry, 53, 1077-1081).
- LPP was shown to be present in a maize (zein) hydrolysate, which had an antihypertensive effect in spontaneously hypertensive rats (M. Shinsuke et al (1991), Agric. Biol. 55(5), 1407-1408).
- IPPeq IPP concentration
- BPPeq BPP concentration
- the process according to the invention involves a step in which a substrate is subjected to treatment with an Aspergillus derived enzyme.
- Substrate is herein defined as the material that is subjected to the enzyme treatment.
- the substrate may be any casein and/or casein fragment containing material suitable as the basis for human food.
- the substrate is milk.
- Animal milk such as cow's milk, goat's milk, camel milk, horse's milk, may be used as substrate. Skim milks may be used.
- the content of the solid in the substrate is not particularly limited, but is usually 5 to 20wt %.
- the substrate may be reconstituted milk, prepared by mixing water and milk ingredients, for instance (skim) milk powder.
- the substrate may contain additives, such as carbohydrates, etc. as long as these additives do not interfere with the enzyme treatment and/or fermentation.
- caseinates such as for instance potassium-caseinate and/or calcium caseinate may be used in a substrate.
- the substrate is fermented milk which may be produced according to the fermentation process described hereinafter.
- casein is first subjected to fermentation and thereafter to enzyme treatment.
- Another embodiment involves that fermentation and enzyme treatment are conducted simultaneously, e.g. by adding the Aspergillus derived enzyme to the fermentor in which the fermentation takes place.
- the enzyme treatment may be done in a conventional manner. It involves adding enzyme (or a mixture of enzymes) to the substrate and maintaining the resulting reaction mixture under controlled conditions suitable for conducting the enzymatic hydrolysis.
- the conditions to be controlled include temperature, pH, reaction time and enzyme concentration.
- the preferred temperature of the reaction mixture is 40-60 degrees C., more preferred 45-55 degrees C. and most preferred about 50 degrees C.
- the pH of the reaction mixture is preferably 5 to 9, more preferably 5.5 to 7 and most preferably 6 to 6.5.
- the enzyme concentration is 2-10 wt. % based on the total weight of the casein, more preferably 3-10 and most preferably 4-6 wt %.
- the reaction time is preferably 2-50 hours, more preferably 2-10 hours and most preferably 4-8 hours.
- the enzyme should be derived from Aspergillus. We have surprisingly found that conducting hydrolysis of casein with a relatively high amount of enzyme derived from Aspergillus results in much higher amounts of the tripeptides VPP, IPP and/or LPP. Preferably the enzyme is derived from Aspergillus oryzae.
- the hydrolysis of casein may be substituted by a fermentation step with Aspergillus.
- Aspergillus it is believed that the fungus Aspergillus will during fermentation produce the enzymes that cause hydrolysis of the casein in situ.
- the fermentation should be conducted in such way that high amounts of enzymes (including endopeptidase, exopeptidase and proteinase) are produced in situ.
- Food products according to the invention are defined as products, suitable for human consumption, in which a casein hydrolysis product according to the invention was used as an ingredient in an effective amount, such that a noticeable ACE-inhibitory effect is obtained.
- the substrate for the enzyme treatment is a fermentation product resulting from Lb. helveticus fermentation.
- the process for preparing the hydrolysed casein product therefore optionally involves a fermentation step.
- the Lb. helveticus fermentation may be executed in conventional fermentors, in which casein containing starting material as a medium is inoculated with the Lb. helveticus.
- the casein containing starting material may be any material containing casein and is preferably a material that may also be used as substrate as defined hereabove, e.g. milk.
- the Lb. helveticus may be any Lb. helveticus strain. Preferred are those strain that produce high amounts of tripeptide VPP and/or IPP. Most preferred is Lactobacillus helveticus strain CNRZ 244, deposited at Centre National deberichts Zootechniques, Jouy-en-Josas, France.
- yeast may additionally be used for improving the flavour and palatability of the resulting hydrolysed casein product.
- yeast of the genus Saccharomyces such as Saccharomyces cerevisiae may preferably be used.
- the content of the yeast may suitably be selected, depending on the desired result.
- the inoculation amount is usually about 10 7 to 10 9 cells of the Lb. helveticus bacteria.
- the Lb. helveticus may be added to the fermentation preferably in the form of a precultured starter having sufficient activity.
- the initial cell count of the starter is preferably about 10 7 to 10 9 cells/ml.
- the materials in the fermentor including Lb. helveticus inoculum and the casein containing starting material, may be mixed in conventional way, in order to achieve a homogeneous fermentation medium.
- the fermentation advantageously may be performed at 25 to 50° C. and preferably 35 to 45° C., for 3 to 80 hours and preferably 6 to 25 hours.
- the fermentation temperature is 38-42° C., since in this temperature range the highest amount of tripeptides VPP and/or IPP is formed.
- the pH during fermentation is critical as to the amount of tripeptides VPP and/or IPP formed.
- the pH during a substantial part of the fermentation is 4.3-4.9, more preferably 4.4-4.8 and most preferably 4.5-4.7.
- a substantial part of the fermentation means in this context at least 1 hour or more of the fermentation time.
- the pH of during fermentation is controlled during 3 hours or more of the fermentation time, more preferably 5 hours or more.
- the pH may be controlled by addition of base (or buffer) to the fermentation medium.
- the base may be any base suitable for use in the preparation of food products.
- Such controlled fermentation is herein called pH-controlled fermentation. Without pH-control is herein called free acidification fermentation.
- Lactic acid (HLa or LaH) dissociates into a proton, H + , and a lactate anion, La—(sometimes referred to herein as dissolved lactate salt when another source of cation is present, typically from the base or buffer salt).
- the amount of dissociation is related to the pH of the solution and the PKa of lactic acid.
- the pKa of lactic acid at 25° C. is 3.86 (at 50° C. it is about 3.89). Equation (2) below describes how the pH, pKa, and degree of lactic acid dissociation are related.
- Equation (2) shows that half the acid is dissociated when the pH equals the pKa of the acid. At higher pH values, the majority of the lactic acid is in the lactate anion form. If the fermentation broth has a pH value between 3.0 and 4.5, there will be a significant amount of lactic acid in the undissociated form. Indeed at a pH of 3.0 the molar ratio of free lactic acid (undissociated) to lactate ion at 25° C. is about 7.0; and, at a pH of about 4.5 the ratio at 25° C., is about 0.23.
- a preferred protocol for pH-controlled fermentation is executed as follows: After inoculation (1) a free acidification fermentation until the desired pH is reached (in range 4.3-4.9), subsequently (2) a pH-controlled fermentation and optionally (3) subsequently a second free acidification fermentation until the termination, e.g at pH 3.5-4.0. As result of this protocol a high amount of equivalent IPP can be produced, while maintaining a relatively low level of salts in the hydrolysed casein product.
- the base is a metal salt, the metal of which is common in food, but does not increase the blood pressure.
- the base is a hydroxide.
- a base containing sodium, such as sodium hydroxide, is therefore preferably excluded.
- the base is a salt chosen from the group consisting of calcium salt, potassium salt and/or magnesium salt.
- the metal ions of such a base K + , Ca 2+ and/or Mg 2+ which as a result of the pH-controlled fermentation will become part of the hydrolysed casein product, may decrease the blood pressure in humans.
- the level of dissolved oxygen (dO 2 ) during fermentation is 5% or less.
- the production of tripeptides VPP and/or IPP is increased, compared to higher oxygen levels.
- the fermentor may be sparged with an inert gas, such as nitrogen in order to accomplish low dissolved oxygen levels.
- solid calcium lactate and/or magnesium lactate may be separated from the hydrolysed casein, e.g. by cooling the hydrolysed casein product, such that these lactates precipitate.
- the hydrolysed casein product may be used as such, or may be diluted, it may be concentrated, it may be purified and it may be dried, preferably spray-dried or freeze-dried.
- the dried hydrolysed casein product is hereafter also designated as hydrolysed casein solids.
- VPP, IPP and/or LPP molecules may be liberated from the substrate.
- the molar yield of VPP on its substrate is 30% or more, preferably 40% or more and more preferably 50% or more.
- the molar yield of VPP is defined as the molar amount of VPP produced in the experiments (fermentation and/or enzymatic hydrolysis) divided by the molar amount of VPP fragments in the total mass of beta-casein present in the casein containing starting material prior to the start of the experiments.
- An analogous calculation gives the molar yield of IPP and LPP. Note that the VPP and the LPP sequence are present in beta-casein, while the IPP sequence is present in both beta- and kappa-casein.
- the molar yield of IPP is preferably 60% or more, more preferably 75% or more and most preferably 80% or more.
- a hydrolysed casein product which comprises an amount of tripeptides VPP, IPP and/or LPP expressed as equivalent IPP concentration [IPPeq] of 200 ⁇ M or more, more preferably 400 ⁇ M or more, even more preferably 600 ⁇ M or more and most preferably 700 to 3500 ⁇ M.
- the molar yield of LPP is 20% or more, more preferably 45% or more, even more preferably 80% or more.
- the food products according to the invention comprise 25 ⁇ M or more LPP.
- the hydrolysed casein product comprises 50-200 mmol/kg K + and/or 15-60 mmol/kg Ca 2+ and/or 6-25 mmol/kg Mg 2+ more preferably, 100-150 mmol/kg K + and/or 30-50 mmol/kg Ca 2+ and/or 10-25 mmol/kg Mg 2+ and most preferably 110-135 mmol/kg K + and/or 35-45 mmol/kg Ca 2+ and/or 13-20 mmol/kg Mg 2+ .
- the addition of these ions will have and anti-hypertensive effect.
- Humans may consume the hydrolysed casein product, or products derived therefrom, as such. They may also be used in a food product as a food ingredient. Preferably, in such case the levels of equivalent IPP concentration and K + , Ca 2+ and Mg 2+ of the food product are within the ranges as defined herein for the hydrolysed casein product.
- hydrolysed casein product according to the invention or food products derived therefrom may be pasteurised or sterilised.
- the food products according to the invention may be of any food type. They may comprise common food ingredients in addition to the hydrolysed casein product, such as flavour, sugar, fruits, minerals, vitamins, stabilisers, thickeners, etc. in appropriate amounts.
- the food products are fruit juice products, dairy type products or frozen confectionary products. These preferred types of food products are described in some detail below and in the examples.
- fruit juice products according to the invention are juices derived from citrus fruit like orange and grapefruit, tropical fruits, banana, peach, peer, strawberry, wherein the solids are partly or fully consisting of hydrolysed casein solids.
- dairy products according to the invention are milk, dairy spreads, cream cheese, milk type drinks and yoghurt, wherein the milk solids are partly or fully consisting of hydrolysed casein solids.
- the hydrolysed casein product may be used as such as a milk type drink. Alternatively flavour or other additives may be added.
- a dairy type product may also be made by adding hydrolysed casein solids to water or to a dairy product.
- composition for a yoghurt type product is about 50-80 wt. % water, 0.1-15 wt. % hydrolysed casein solids, 0-15 wt. % whey powder, 0-15 wt. % sugar (e.g. sucrose), 0.01-1 wt. % yoghurt culture, 0-20 wt. % fruit, 0.05-5 wt. % vitamins and minerals, 0-2 wt. % flavour, 0-5 wt. % stabilizer (thickener or gelling agent).
- sugar e.g. sucrose
- sugar e.g. sucrose
- 0.01-1 wt. % yoghurt culture 0-20 wt. % fruit
- 0.05-5 wt. % vitamins and minerals 0-2 wt. % flavour, 0-5 wt. % stabilizer (thickener or gelling agent).
- a typical serving size for a yoghurt type product could be from 50 to 250 g, generally from 80 to 200 g.
- frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- the level of solids in the frozen confection is more than 3 wt. %, more preferred from 10 to 70 wt. %, for example 40 to 70 wt. %.
- Ice cream will typically comprise 0 to 20 wt. % of fat, 0.1 to 20 wt. % hydrolysed casein solids, sweeteners, 0 to 10 wt. % of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water.
- ice cream will be aerated e.g. to an overrun of 20 to 400%, more specific 40 to 200% and frozen to a temperature of from ⁇ 2 to ⁇ 200° C., more specific ⁇ 10 to ⁇ 30° C. Ice cream normally comprises calcium at a level of about 0.1 wt %.
- Other food product according to the invention can be prepared by the skilled person based on common general knowledge, using hydrolysed casein or hydrolysed casein derived products, such as hydrolysed casein solids as an ingredient in suitable amounts.
- hydrolysed casein or hydrolysed casein derived products such as hydrolysed casein solids as an ingredient in suitable amounts.
- examples of such food products are baked goods, dairy type foods, snacks, etc.
- the food product is an oil and water containing emulsion, for instance a spread.
- Oil and water emulsion is herein defined as an emulsion comprising oil and water and includes oil in water (O/W) emulsions and water in oil emulsions (W/O) and more complex emulsions for instance water-in-oil-in-water (W/O/W/O/W) emulsions.
- Oil is herein defined as including fat.
- the food product is a spread, frozen confection, or sauce.
- a spread according to the invention comprises 30-90 wt. % vegetable oil.
- a spread has a pH of 4.2-6.0.
- the ion source of the MS was operating in positive-electrospray mode.
- the product ions m/z 213.1 and m/z 183.1 were monitored in MRM of the precursor ion m/z 326.3 for IPP and LPP, m/z 213.1 and m/z 169.1 for VPP and m/z 213.1 and m/z 189.1 for the internal standard UC13IPP.
- the cone voltage and collision energy was 20 V and 20 eV for all compounds.
- the collision gas used was Argon, and the collision gas pressure was 2.3 ⁇ 10 ⁇ 3 mbar.
- the quantification was performed using a separate relative internal calibration curve for both compounds.
- Proteinase activity of the enzyme mixtures was determined using a Universal Protease Casein resorufin-labeled (ex Boehringer Mannheim) as a substrate. This assay is based on the principle resorufin-labeled peptides are released over time by degradation of the resorufin labeled casein using proteinases.
- a 50 ⁇ L labeled substrate solution, a 50 ⁇ L 100 mM sodium phosphate buffer of pH 7.0 and 100 ⁇ L of enzyme solution in the appropriate dilution were mixed and incubated at 50° C. for 60 minutes.
- the remaining resorufin labeled casein was precipitated by addition of tricloroacetic acid and centrifugation (14000 rpm for 10 minutes).
- An 80 ⁇ L sample of the supernatant was added to 120 ⁇ L assay buffer (pH 8.8) and absorbance was read at 574 nm.
- the X-prolyl dipeptidyl amino activity of the enzyme mixtures was measured using a 1 mM Glycine-Proline-para Nitroaniline (GP-pNa) substrate solution in a 100 mM sodium phosphate buffer at pH 7.0 by incubating enzyme samples in an appropriate dilution at 50° C. and monitoring the absorbance at 405 nm for 20 minutes.
- the enzyme activity was calculated in units from the increase of absorbance using the molar extinction coefficient of para-nitroaniline which is 9620 M ⁇ 1 cm ⁇ 1 .
- the X-prolyl dipeptidyl amino activity is expressed as U/kg.
- the conversion of 1 ⁇ Mol GP-pNa per min by the crude enzyme mixture represents 1 U.
- the presence of the total amount of amino groups, as free amino acids, peptides and proteins in hydrolysed casein samples is used to evaluate the total proteolysis after enzymatic hydrolysis and/or fermentation using lactic acid bacteria.
- a method to determine a degree of hydrolysis in food protein hydrolysates described by Adler-Nissen J. in Agric. Food Chem. 27, 1256-1262 (1979) was used.
- a volume of 5 ⁇ L sample, 5 ⁇ L leucine standard (0.25-2.5 mM) or 5 ⁇ L demineralised water were added to 40 ⁇ L of 0.21 M phosphate buffer pH 8.2 and 40 ⁇ L of 0.1 wt % TNBS solution, followed by incubation in the dark for 60 minutes at 50° C. The reaction is quenched by adding 80 ⁇ L of 0.1 M HCl. Absorbance was measured at 340 nm (Adler-Nissen J. Enzymatic hydrolysis of food proteins. New York: Elsevier Applied Science Publishers p. 110-169 (1986)).
- the total amount of amino groups present in the hydrolysed casein products was expressed as mM Leucine equivalents.
- DH degree of hydrolysis
- Skimmed milk (9% SMP) was reconstituted by mixing 9 wt % skim milk powder (Promex, ex Coberco, Netherlands) in tap water and sterilised. The sterile reconstituted skim milk was incubated at 50° C. for 6 hours at pH 7.0 with either 0.16 wt % (5 wt % based on casein) Fungal Protease Concentrate (ex Genencor) or 0.16 wt % (5 wt % based on casein) Umamizyme (ex Amano). Both enzyme mixtures are derived from Aspergillus oryzae, and are comprised of proteinases and peptidases.
- a casein starting material was fermented with Lactobacillus helveticus CNRZ 244 and the resulting fermented milk herein also designated as fermented milk substrate was treated with enzymes mentioned in table 1.
- Sterile skim milk (Yopper ex Campina, Netherlands) was inoculated for 24 hours at 37° C. with 4% of a culture of a Lactobacillus helveticus CNRZ 244 that had been stored at ⁇ 80° C. as a full grown culture in the above described skim milk, diluted with sterile 10% glycerol to an end concentration of 6% glycerol. This preculture was designated as preculture-1
- preculture-2 was prepared with sterile skim milk (Yopper, ex Campina, Netherlands), which was inoculated with 2 wt % preculture-1 of Lactobacillus helveticus CNRZ 244. Preculture-2 was stirred and incubated at 40° C. for 24 hours under anaerobic conditions, using a headspace nitrogen gas flush.
- Skimmed milk was reconstituted by mixing 9 wt % skim milk powder (Promex, ex Coberco, Netherlands) in tap water and sterilised. The sterile reconstituted milk was inoculated with 2 wt % of preculture-2 in a stirred tank reactor. Stirred speed was maintained at 150 rpm and dissolved oxygen and pH were monitored.
- Anaerobic conditions were maintained using a headspace flush with nitrogen gas. During the first 8 hours of fermentation the pH of the milk was allowed to decrease from pH 6.5 to pH 4.6. At pH 4.6 the pH was controlled for 3.5 hours, using a base mixture of calciumhydroxide and potassiumhydroxide. After this pH controlled phase the pH was again allowed to decrease to 4.0.
- the pasteurised fermented milk product is designated as fermented milk substrate in comparative example A.
- the fermented milk substrate was incubated with 0.16 wt % (5 wt % based on casein) of the various enzyme mixtures comprising of proteinases and peptidases at 50° C. for six hours at pH 7.
- Results from examples 1-5 show both milk and fermented milk incubated with enzyme mixtures derived from Aspergillus and more in particular Aspergillus oryzae give rise to high IPP, LPP and VPP levels.
- the molar yield of LPP on beta-casein was found to be higher than 20% in examples 1 to 5.
- Examples 1, 2, 4 and 5 all show high levels of IPP, VPP and LPP and thus high corresponding IPPeq and BPPeq values were determined.
- the enzyme was derived from Aspergillus Oryzae.
- Example 2 shows high levels of IPP, LPP and VPP can be obtained by incubation reconstituted milk with Umamizyme (ex Amano). Furthermore high molar yields of VPP and LPP of 80% and 84% respectively were found in example 2.
- the high values for total proteolysis in examples 1, 2, 4 and 5 correspond to a high degree of hydrolysis of 37 to 55% of the milk proteins.
- the comparative examples B-H showed a decrease in concentration of the bio-active peptides IPP and VPP after incubation with the proteinase and peptidase mixtures, compared to the concentrations present in the fermented milk substrate (example A). No formation of LPP could be shown in these comparative examples B to H.
- hydrolysed casein products obtained according to examples 1 and 4 were used to produce milk and fermented milk drinks.
- the milk drinks contained 12.5 wt % of hydrolysed casein products in pasteurised skim milk and the following ingredients: 4.5 wt % sucrose (ex CSM, Netherlands), 1 wt % fructose syrup (ex Sensus, Netherlands), 2 wt % Multifruit fruitpulp (ex Wild, Netherlands), 0.1 wt % yoghurt flavour ZD-49492 (ex Quest, Netherlands), 0.03 wt % fruit flavour 037-00330-11 (ex Givaudan, Switzerland), 0.1 wt % cream flavour U33162 (ex Danisco, Denmark) and 0.8 wt. % Genu pectine YM-115-H (ex CP Kelco, Denmark).
- the milk drinks were homogenised at 150 bar and pasteurised for 15 seconds at 75° C.
- the taste of the milk drinks was good. No bitterness was noticed.
- hydrolysed casein solids was prepared as described herein:
- a reactor was filled with 10 wt % calcium caseinate (ex DMV, Netherlands), pasteurised at 85° C. for 20 minutes, cooled to 50° C. and incubated under anaerobic conditions with 0.5% wt Umamizyme (ex Amano) for 6 hours at 50° C.
- the pH of the hydrolysate was adjusted from pH 6.2 to pH 4 using 80% wt lactic acid (ex Purac, Netherlands) and the remaining enzymes were deactivated by heating the hydrolysate at 95° C. for 20 minutes. Prior to freeze drying the hydrolysate was stored at ⁇ 20° C.
- the yoghurt drink contained 60 wt % low fat yoghurt (ex Melkan, Netherlands); 9 wt % sucrose (ex CSM, Netherlands); 0.35 wt % AMD 783 pectine (ex Danisco, Denmark); 1.23 wt % hydrolysed casein solids; 0.025 wt % raspberry 502824 A (ex Firmenich, Switserland) and 29.4 wt % demineralised water.
- the yoghurt drink was homogenised at 150 bar and pasteurised for 15 seconds at 75° C.
- the final VPP, IPP and LPP content of the yoghurt drink was 66 ⁇ M, 100 ⁇ M and 76 ⁇ M respectively.
- the taste of the yoghurt drink containing 1.23 wt % hydrolysed casein solids was good and no bitter taste was noticed.
- the 3.2 wt %; 6 wt % and 10 wt % casein substrates were prepared by mixing in appropriate levels of calcium caseinate (ex DMV, Netherlands) in tap water.
- a high skim milk (18% SMP) substrate was prepared by mixing 18 wt % skim milk powder (ex Coberco, Netherlands) in tap water. All substrates, 18% SMP and the casein substrates were incubated at 50° C. for six hours. Prior to these incubations the pH was adjusted to pH 7.0. All substrates were incubated with Umamizyme (ex Amano), the ratio enzyme mixture to casein was 5 wt %.
- results from examples 9, 10 and 11 clearly show increased amounts of casein substrate lead to higher levels of the bio-active peptides VPP, IPP and LPP and to very high corresponding IPPeq and BPPeq values.
- casein substrate levels With increasing casein substrate levels the molar yields of VPP, IPP and LPP on casein decreased although the resulting molar yields at the highest level of casein substrate (10 wt %) are still above 50%.
- the substrate used in these incubations contained 10 wt % casein and was prepared by mixing an appropriate level of calcium caseinate (ex DMV, Netherlands) in tap water. The incubation was performed at 50° C. for six hours and prior to these incubations the pH was not adjusted. All incubation were performed using the Umamizyme (ex Amano) enzyme mixture, the ratio enzyme mixture to casein used were 1 wt %; 2.5 wt %; 4 wt % and 5 wt %.
- results from example 13-15 and comparative example J indicate an enzyme to substrate ratio over 1% is needed to obtain high yields of VPP, IPP and LPP on the casein substrate.
- VPP very high levels
- IPP and LPP were obtained.
- the highest levels VPP, IPP and LPP were obtained corresponding to an IPPeq value of 1531 ⁇ M and a BPPeq value of 1955 ⁇ M.
- Comparative example K was executed according to example 15 with an enzyme to substrate ratio of 5% based on casein, except in this case a different enzyme mixture is used.
- a 10% casein solution was incubated using Flavourzyme (ex Novozymes) instead of Umamizyme (ex Amano). After the incubation the bioactive peptide VPP and the degree of hydrolysis were determined.
- Flavourzyme ex Novozymes
- Umamizyme ex Amano
- Results indicate besides a high proteolytic activity a relatively high X-prolyl dipeptidyl amino peptidase activity is needed to obtain high levels of the active tripeptide VPP.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
- The invention relates to a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP. The invention further relates to a process for the preparation of such hydrolysed casein product and to food products produced using the hydrolysed casein product.
- Hypertension or high blood pressure is considered to be one of the main risk factors for Cardio Vascular Diseases (CVD). One of the mechanisms which regulates blood pressure is the renin-angiotensin system. This is a cascade of reactions leading to the formation of angiotensin II, which has a strong vasoconstrictive and hence blood pressure increasing effect. Inhibition of one of the key enzymes in this cascade:
- Angiotensin I Converting Enzyme (ACE) reduces formation of angiotensin II and thus has a blood pressure lowering effect. Long term human intervention studies have shown regular intake of low amounts of ACE inhibitors reduces CVD by 25% (Gerstein et al. (2000), The Lancet 355, 253-259).
- In a placebo-controlled study, the blood pressure lowering effect of VPP and IPP in sour milk was shown in hypertensive humans (Hata, Y et al. (1996), American Journal of Clinical Nutrition 64, 767-771).
- A commercially available fermented milk product, which claims to be “suitable for those with mild hypertension” is Calpis sour milk, fermented with Lactobacillus helveticus and Saccharomyces cervisiae, produced by Calpis Food Industry, Japan.
- Another commercially available fermented milk product is Evolus produced by Valio, Finland, which claims to be ‘the first European functional food to help lower blood pressure’.
- Both fermented milk products are fermented with Lactobacillus helveticus (Lb. helveticus) strains. The products contain bioactive peptides (VPP and IPP) responsible for in vitro ACE inhibition, which are produced by proteolysis of caseins. Compared to other lactic acid bacteria Lb. helveticus is one of the most efficient proteolytic Lactobacillus species.
- The breakdown of caseins by the proteolytic system of lactic acid bacteria can be divided into three stages. Initially breakdown of casein is performed by extracellular proteinases, followed by the uptake of di/tri peptides and oligopeptides (4 to 12 amino acidic residues) using specific uptake mechanisms. In the last stage, peptides are further degraded by intracellular peptidases, yielding small peptides and amino acids for bacterial growth. This complicated proteolytic system of lactic acid bacteria is described in Kunji et al., (1996), Molecular Microbiology 27, 1107-1118. A review on the intracellular peptidase system can be found in Christensen et al., (1999), Molecular Microbiology 76, 217-246.
- According to EP-A-1016709, it is desired to produce fermented milk with higher content of the lactotripeptides compared to the content of the lactic acid generated in the fermented milk. It provides a Lactobacillus helveticus strain CM4 that in fermentation gives 30-50 μg of tripeptides Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) per 0.01 g of DL-lactic acid. In table 2 of EP-A-1016709 it is shown that this strain produced 38.5 μg/ml whey of VPP and 23.5 μg/ml whey IPP, which corresponds to an IPPeq value, as defined hereinafter, of 140.
- WO 01/034828 discloses a process for producing tripeptides VPP and/or IPP starting from casein using enzymes. In the process casein is treated with proteinase to produce an intermediate peptide and then digesting the intermediate peptide with peptidase. The best results in WO 01/034828 are shown in example 2 where casein hydrolysed with papain and Lactobacillus helveticus derived peptidase gives a VPP yield is 25% and the IPP yield 97.5%, based on beta-casein. Assuming an average content of 30 wt. % beta-casein and 15 wt. % kappa-casein in skim milk powder, the yield of IPP yield of 97.5% based on beta-casein corresponds to a yield of 54% based on beta-casein and kappa casein together, as used herein. In the other examples lower yields are reported.
- It is an object of the invention to provide a food product having a high content of tripeptides VPP, IPP and/or LPP. In view of WO01/034828 it is an object to increase the yield of the tripeptides VPP and/or IPP. It is another object to provide a process for the preparation of a food product comprising VPP, IPP and/or LPP that is simple and low cost. Another object is to provide a food product having a good taste.
- One or more of these objects are attained according to the invention, which provides a process for the preparation of a hydrolysed casein product comprising tripeptides VPP, IPP and/or LPP, wherein a substrate comprising casein or casein fragments is subjected to enzyme treatment wherein the enzyme is derived from Aspergillus, wherein the enzyme concentration is 2-10 wt. % based on casein and that the enzyme has a high proteolytic activity.
- According to a preferred embodiment the enzyme comprises endopeptidases, exopeptidases and proteinases.
- The invention further relates to a hydrolysed casein food product comprising 200 μM or more of IPPeq, preferably 400 μM or more of IPPeq as defined hereafter. Advantageously the hydrolysed casein food product has a non-bitter taste.
- The weight percentages herein will be expressed relative to the total weight, unless otherwise indicated.
- Enzyme is herein understood to also include a mixture of more than one enzyme.
- The common one letter code is ordinarily used to describe amino acids.
- Casein is herein understood to include all types of casein, including alpha casein, beta casein, gamma casein and kappa casein. It is noted that the fragment IPP occurs in both beta- and kappa-casein. The fragments VPP and LPP both occur once in beta casein.
- Substrate herein means any material containing casein and/or casein fragments, when used as the material treated with the enzyme.
- Proteases are herein any of a group of enzymes that cleave peptide bonds of proteins (polypeptides) resulting in shorter peptides and amino acids.
- Exopeptidase is herein defined as an enzyme that acts only near the ends of polypeptide chains. Based on their site of action at the N or C terminus they are classified as amino- or carboxypeptidases, respectively.
- Endopeptidase is herein defined as an enzyme that acts preferentially at the peptide bonds in the inner regions of the polypeptide chains away from the N and C termini.
- High proteolytic activity of the enzyme is herein defined as a proteolytic activity corresponding to a degree of hydrolysis of 20% or higher as measured in accordance with the experimental part of this specification, at a hydrolysis time of 6 hours and en enzyme concentration of 5 wt. % based on casein.
- Preferably the enzyme has a X-Prolyl dipeptidyl aminopeptidase activity or 400 U/kg or more, more preferably 700 U/kg or more, even more preferably 1200 u/kg or more.
- The peptide Val-Pro-Pro is abbreviated as VPP; the peptide Ile-Pro-Pro as IPP and Leu-Pro-Pro as LPP. Lactobacillus is herein abbreviated as Lb.
- Tripeptides VPP, IPP and/or LPP as defined herein include VPP, IPP, LPP and mixtures of these peptides. The total molar amount of tripeptides VPP, IPP and/or LPP in mixtures are herein calculated by addition of molar amounts of the tripeptides in the mixture.
- The process according to the invention produces the active tripeptides VPP, IPP, and LPP, which have a different activity. The IC50, the concentration which results in 50% inhibition of the ACE activity is 5 μM for IPP and 9 μM for VPP (Kohmura, M. et al. (1990), Agricultrural and Biochemical Chemistry, 54, 835-836 and Nakamura, Y et al. (1995), J. Dairy Sci. 78, 1253-1257). The IC50 ACE inhibition value for LPP is 9.6 μM (Maruyama S. et al. (1989), Agricultural and Biochemical Chemistry, 53, 1077-1081). LPP was shown to be present in a maize (zein) hydrolysate, which had an antihypertensive effect in spontaneously hypertensive rats (M. Shinsuke et al (1991), Agric. Biol. 55(5), 1407-1408).
- To express the overall concentration of these active peptides IPP and VPP in a single figure, the equivalent IPP concentration [IPPeq] is used herein, which is defined as follows and preferably expressed in μM:
-
[IPPeq]=[IPP]+5/9*[VPP] (1) - To express the overall concentration of all active tripeptides containing a branched chain amino acid -Proline-Proline sequence e.g. IPP, VPP and LPP, the equivalent BPP concentration (BPPeq) is also used herein, which is defined as follows and expressed in μM:
-
BPPeq=[IPP]+5/9*[VPP]+5/9.6*[LPP] (2) - The process according to the invention involves a step in which a substrate is subjected to treatment with an Aspergillus derived enzyme. Substrate is herein defined as the material that is subjected to the enzyme treatment.
- The substrate may be any casein and/or casein fragment containing material suitable as the basis for human food.
- Preferably the substrate is milk. Animal milk such as cow's milk, goat's milk, camel milk, horse's milk, may be used as substrate. Skim milks may be used. The content of the solid in the substrate is not particularly limited, but is usually 5 to 20wt %. The substrate may be reconstituted milk, prepared by mixing water and milk ingredients, for instance (skim) milk powder. The substrate may contain additives, such as carbohydrates, etc. as long as these additives do not interfere with the enzyme treatment and/or fermentation.
- Preferably caseinates, such as for instance potassium-caseinate and/or calcium caseinate may be used in a substrate.
- In a preferred embodiment the substrate is fermented milk which may be produced according to the fermentation process described hereinafter. In this preferred embodiment casein is first subjected to fermentation and thereafter to enzyme treatment.
- Another embodiment involves that fermentation and enzyme treatment are conducted simultaneously, e.g. by adding the Aspergillus derived enzyme to the fermentor in which the fermentation takes place.
- The enzyme treatment may be done in a conventional manner. It involves adding enzyme (or a mixture of enzymes) to the substrate and maintaining the resulting reaction mixture under controlled conditions suitable for conducting the enzymatic hydrolysis. The conditions to be controlled include temperature, pH, reaction time and enzyme concentration. The preferred temperature of the reaction mixture is 40-60 degrees C., more preferred 45-55 degrees C. and most preferred about 50 degrees C. The pH of the reaction mixture is preferably 5 to 9, more preferably 5.5 to 7 and most preferably 6 to 6.5. The enzyme concentration is 2-10 wt. % based on the total weight of the casein, more preferably 3-10 and most preferably 4-6 wt %. The reaction time (hydrolysis time) is preferably 2-50 hours, more preferably 2-10 hours and most preferably 4-8 hours. The enzyme should be derived from Aspergillus. We have surprisingly found that conducting hydrolysis of casein with a relatively high amount of enzyme derived from Aspergillus results in much higher amounts of the tripeptides VPP, IPP and/or LPP. Preferably the enzyme is derived from Aspergillus oryzae.
- In another preferred embodiment the hydrolysis of casein may be substituted by a fermentation step with Aspergillus. In this preferred embodiment it is believed that the fungus Aspergillus will during fermentation produce the enzymes that cause hydrolysis of the casein in situ. In this preferred embodiment the fermentation should be conducted in such way that high amounts of enzymes (including endopeptidase, exopeptidase and proteinase) are produced in situ.
- Food products according to the invention are defined as products, suitable for human consumption, in which a casein hydrolysis product according to the invention was used as an ingredient in an effective amount, such that a noticeable ACE-inhibitory effect is obtained.
- According to this preferred embodiment the substrate for the enzyme treatment is a fermentation product resulting from Lb. helveticus fermentation. The process for preparing the hydrolysed casein product therefore optionally involves a fermentation step.
- The Lb. helveticus fermentation may be executed in conventional fermentors, in which casein containing starting material as a medium is inoculated with the Lb. helveticus. The casein containing starting material may be any material containing casein and is preferably a material that may also be used as substrate as defined hereabove, e.g. milk.
- The conditions of the fermentation step are specified below. The Lb. helveticus may be any Lb. helveticus strain. Preferred are those strain that produce high amounts of tripeptide VPP and/or IPP. Most preferred is Lactobacillus helveticus strain CNRZ 244, deposited at Centre National de Recherches Zootechniques, Jouy-en-Josas, France.
- Other microorganisms may optionally be added to the fermentation medium as long as the object of the present invention is achieved. For example, yeast may additionally be used for improving the flavour and palatability of the resulting hydrolysed casein product.
- Strains of the yeast are not particularly limited, and for example, yeast of the genus Saccharomyces such as Saccharomyces cerevisiae may preferably be used. The content of the yeast may suitably be selected, depending on the desired result.
- There is no particular limitation on the amount of the Lb. helveticus with which the medium is inoculated. The inoculation amount is usually about 107 to 109 cells of the Lb. helveticus bacteria.
- The Lb. helveticus may be added to the fermentation preferably in the form of a precultured starter having sufficient activity. The initial cell count of the starter is preferably about 107 to 109 cells/ml.
- The materials in the fermentor, including Lb. helveticus inoculum and the casein containing starting material, may be mixed in conventional way, in order to achieve a homogeneous fermentation medium.
- The fermentation advantageously may be performed at 25 to 50° C. and preferably 35 to 45° C., for 3 to 80 hours and preferably 6 to 25 hours. Preferably the fermentation temperature is 38-42° C., since in this temperature range the highest amount of tripeptides VPP and/or IPP is formed.
- The pH during fermentation is critical as to the amount of tripeptides VPP and/or IPP formed. Preferably therefore, the pH during a substantial part of the fermentation is 4.3-4.9, more preferably 4.4-4.8 and most preferably 4.5-4.7. A substantial part of the fermentation means in this context at least 1 hour or more of the fermentation time. Preferably the pH of during fermentation is controlled during 3 hours or more of the fermentation time, more preferably 5 hours or more.
- The pH may be controlled by addition of base (or buffer) to the fermentation medium. The base may be any base suitable for use in the preparation of food products. Such controlled fermentation is herein called pH-controlled fermentation. Without pH-control is herein called free acidification fermentation.
- During the fermentation, Lb. helveticus produces amongst others lactic acid. Lactic acid (HLa or LaH) dissociates into a proton, H+, and a lactate anion, La—(sometimes referred to herein as dissolved lactate salt when another source of cation is present, typically from the base or buffer salt). The amount of dissociation is related to the pH of the solution and the PKa of lactic acid. The pKa of lactic acid at 25° C. is 3.86 (at 50° C. it is about 3.89). Equation (2) below describes how the pH, pKa, and degree of lactic acid dissociation are related.
-
pH=pK a+log([La − ]/[LaH]) (3) - Equation (2) shows that half the acid is dissociated when the pH equals the pKa of the acid. At higher pH values, the majority of the lactic acid is in the lactate anion form. If the fermentation broth has a pH value between 3.0 and 4.5, there will be a significant amount of lactic acid in the undissociated form. Indeed at a pH of 3.0 the molar ratio of free lactic acid (undissociated) to lactate ion at 25° C. is about 7.0; and, at a pH of about 4.5 the ratio at 25° C., is about 0.23.
- A preferred protocol for pH-controlled fermentation is executed as follows: After inoculation (1) a free acidification fermentation until the desired pH is reached (in range 4.3-4.9), subsequently (2) a pH-controlled fermentation and optionally (3) subsequently a second free acidification fermentation until the termination, e.g at pH 3.5-4.0. As result of this protocol a high amount of equivalent IPP can be produced, while maintaining a relatively low level of salts in the hydrolysed casein product.
- Preferably the base is a metal salt, the metal of which is common in food, but does not increase the blood pressure. Preferably the base is a hydroxide. A base containing sodium, such as sodium hydroxide, is therefore preferably excluded. More preferably the base is a salt chosen from the group consisting of calcium salt, potassium salt and/or magnesium salt. The metal ions of such a base K+, Ca2+ and/or Mg2+, which as a result of the pH-controlled fermentation will become part of the hydrolysed casein product, may decrease the blood pressure in humans.
- Preferably the level of dissolved oxygen (dO2) during fermentation is 5% or less. At low dissolved oxygen levels the production of tripeptides VPP and/or IPP is increased, compared to higher oxygen levels. The fermentor may be sparged with an inert gas, such as nitrogen in order to accomplish low dissolved oxygen levels.
- Advantageously, after enzyme treatment and optional fermentation, several additional process steps may be executed. For instance, solid calcium lactate and/or magnesium lactate may be separated from the hydrolysed casein, e.g. by cooling the hydrolysed casein product, such that these lactates precipitate. The hydrolysed casein product may be used as such, or may be diluted, it may be concentrated, it may be purified and it may be dried, preferably spray-dried or freeze-dried. The dried hydrolysed casein product is hereafter also designated as hydrolysed casein solids.
- According to the invention a relatively high number of VPP, IPP and/or LPP molecules may be liberated from the substrate. Preferably, the molar yield of VPP on its substrate is 30% or more, preferably 40% or more and more preferably 50% or more.
- The molar yield of VPP is defined as the molar amount of VPP produced in the experiments (fermentation and/or enzymatic hydrolysis) divided by the molar amount of VPP fragments in the total mass of beta-casein present in the casein containing starting material prior to the start of the experiments. An analogous calculation gives the molar yield of IPP and LPP. Note that the VPP and the LPP sequence are present in beta-casein, while the IPP sequence is present in both beta- and kappa-casein.
- The molar yield of IPP is preferably 60% or more, more preferably 75% or more and most preferably 80% or more.
- With the process of the invention, a hydrolysed casein product is obtainable, which comprises an amount of tripeptides VPP, IPP and/or LPP expressed as equivalent IPP concentration [IPPeq] of 200 μM or more, more preferably 400 μM or more, even more preferably 600 μM or more and most preferably 700 to 3500 μM.
- Preferably, in the process for the preparation of the hydrolysed casein product according to the invention, the molar yield of LPP is 20% or more, more preferably 45% or more, even more preferably 80% or more. Preferably the food products according to the invention comprise 25 μM or more LPP.
- Preferably, the hydrolysed casein product comprises 50-200 mmol/kg K+ and/or 15-60 mmol/kg Ca2+ and/or 6-25 mmol/kg Mg2+ more preferably, 100-150 mmol/kg K+ and/or 30-50 mmol/kg Ca2+ and/or 10-25 mmol/kg Mg2+ and most preferably 110-135 mmol/kg K+ and/or 35-45 mmol/kg Ca2+ and/or 13-20 mmol/kg Mg2+. The addition of these ions will have and anti-hypertensive effect.
- Humans may consume the hydrolysed casein product, or products derived therefrom, as such. They may also be used in a food product as a food ingredient. Preferably, in such case the levels of equivalent IPP concentration and K+, Ca2+ and Mg2+ of the food product are within the ranges as defined herein for the hydrolysed casein product.
- The hydrolysed casein product according to the invention or food products derived therefrom may be pasteurised or sterilised.
- The food products according to the invention may be of any food type. They may comprise common food ingredients in addition to the hydrolysed casein product, such as flavour, sugar, fruits, minerals, vitamins, stabilisers, thickeners, etc. in appropriate amounts. Preferably the food products are fruit juice products, dairy type products or frozen confectionary products. These preferred types of food products are described in some detail below and in the examples.
- Fruit Juice Products
- Examples of fruit juice products according to the invention are juices derived from citrus fruit like orange and grapefruit, tropical fruits, banana, peach, peer, strawberry, wherein the solids are partly or fully consisting of hydrolysed casein solids.
- Dairy Type Products
- Examples of dairy products according to the invention are milk, dairy spreads, cream cheese, milk type drinks and yoghurt, wherein the milk solids are partly or fully consisting of hydrolysed casein solids. The hydrolysed casein product may be used as such as a milk type drink. Alternatively flavour or other additives may be added. A dairy type product may also be made by adding hydrolysed casein solids to water or to a dairy product.
- An example of a composition for a yoghurt type product is about 50-80 wt. % water, 0.1-15 wt. % hydrolysed casein solids, 0-15 wt. % whey powder, 0-15 wt. % sugar (e.g. sucrose), 0.01-1 wt. % yoghurt culture, 0-20 wt. % fruit, 0.05-5 wt. % vitamins and minerals, 0-2 wt. % flavour, 0-5 wt. % stabilizer (thickener or gelling agent).
- A typical serving size for a yoghurt type product could be from 50 to 250 g, generally from 80 to 200 g.
- Frozen Confectionery Products
- For the purpose of the invention the term frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- Preferably the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 3 wt. %, more preferred from 10 to 70 wt. %, for example 40 to 70 wt. %.
- Ice cream will typically comprise 0 to 20 wt. % of fat, 0.1 to 20 wt. % hydrolysed casein solids, sweeteners, 0 to 10 wt. % of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water. Typically ice cream will be aerated e.g. to an overrun of 20 to 400%, more specific 40 to 200% and frozen to a temperature of from −2 to −200° C., more specific −10 to −30° C. Ice cream normally comprises calcium at a level of about 0.1 wt %.
- Other food product according to the invention can be prepared by the skilled person based on common general knowledge, using hydrolysed casein or hydrolysed casein derived products, such as hydrolysed casein solids as an ingredient in suitable amounts. Examples of such food products are baked goods, dairy type foods, snacks, etc.
- Advantageously the food product is an oil and water containing emulsion, for instance a spread. Oil and water emulsion is herein defined as an emulsion comprising oil and water and includes oil in water (O/W) emulsions and water in oil emulsions (W/O) and more complex emulsions for instance water-in-oil-in-water (W/O/W/O/W) emulsions. Oil is herein defined as including fat.
- Preferably the food product is a spread, frozen confection, or sauce.
- Preferably a spread according to the invention comprises 30-90 wt. % vegetable oil. Advantageously a spread has a pH of 4.2-6.0.
- Determination of Amounts of IPP, IPPL, LPP and VPP
- Quantification of IPP, IPPL, LPP and VPP was performed using HPLC-MRM-MS in positive ESI mode. The samples were analysed using a HP1100 (ex Agilent) HPLC system combined with a Quattro-II triple quadrupole mass spectrometer (ex Micromass UK). The samples were injected on a Varian 150×2.1 mm Inertsil ODS-3 column prepacked by GL_Sciences. The eluent gradient was linear from 100% water containing 0.1% trifluoric acid (TFA) to 100% of acetonitrile containing 0.1% of TFA in 46 minutes with a flow rate of 0.2 ml/min at a column temperature of 60° C. The ion source of the MS was operating in positive-electrospray mode. The product ions m/z 213.1 and m/z 183.1 were monitored in MRM of the precursor ion m/z 326.3 for IPP and LPP, m/z 213.1 and m/z 169.1 for VPP and m/z 213.1 and m/z 189.1 for the internal standard UC13IPP. The cone voltage and collision energy was 20 V and 20 eV for all compounds. The collision gas used was Argon, and the collision gas pressure was 2.3×10−3 mbar. The quantification was performed using a separate relative internal calibration curve for both compounds.
- Proteinase Activity:
- Proteinase activity of the enzyme mixtures was determined using a Universal Protease Casein resorufin-labeled (ex Boehringer Mannheim) as a substrate. This assay is based on the principle resorufin-labeled peptides are released over time by degradation of the resorufin labeled casein using proteinases.
- A 50 μL labeled substrate solution, a 50 μL 100 mM sodium phosphate buffer of pH 7.0 and 100 μL of enzyme solution in the appropriate dilution were mixed and incubated at 50° C. for 60 minutes. The remaining resorufin labeled casein was precipitated by addition of tricloroacetic acid and centrifugation (14000 rpm for 10 minutes). An 80 μL sample of the supernatant was added to 120 μL assay buffer (pH 8.8) and absorbance was read at 574 nm.
- Several dilutions of one enzyme mixture were tested in this manner to establish a linear curve between the formed absorbance at 574 nm after 60 minutes incubation and the amount of enzyme mixture (μg). The proteinase activity was expressed in arbitrary units (AU), which was calculated by multiplying the slope of the linear curve by 10000. The specific proteinase activity was expressed as arbitrary units per μg enzyme mixture (AU/μg).
- X-Prolyl Dipeptidyl Aminopeptidase Activity:
- The X-prolyl dipeptidyl amino activity of the enzyme mixtures was measured using a 1 mM Glycine-Proline-para Nitroaniline (GP-pNa) substrate solution in a 100 mM sodium phosphate buffer at pH 7.0 by incubating enzyme samples in an appropriate dilution at 50° C. and monitoring the absorbance at 405 nm for 20 minutes. The enzyme activity was calculated in units from the increase of absorbance using the molar extinction coefficient of para-nitroaniline which is 9620 M−1cm−1. The X-prolyl dipeptidyl amino activity is expressed as U/kg. The conversion of 1 μMol GP-pNa per min by the crude enzyme mixture represents 1 U.
- Proteolytic Activity:
- The presence of the total amount of amino groups, as free amino acids, peptides and proteins in hydrolysed casein samples is used to evaluate the total proteolysis after enzymatic hydrolysis and/or fermentation using lactic acid bacteria. A method to determine a degree of hydrolysis in food protein hydrolysates described by Adler-Nissen J. in Agric. Food Chem. 27, 1256-1262 (1979) was used.
- A volume of 5 μL sample, 5 μL leucine standard (0.25-2.5 mM) or 5 μL demineralised water were added to 40 μL of 0.21 M phosphate buffer pH 8.2 and 40 μL of 0.1 wt % TNBS solution, followed by incubation in the dark for 60 minutes at 50° C. The reaction is quenched by adding 80 μL of 0.1 M HCl. Absorbance was measured at 340 nm (Adler-Nissen J. Enzymatic hydrolysis of food proteins. New York: Elsevier Applied Science Publishers p. 110-169 (1986)).
- The total amount of amino groups present in the hydrolysed casein products was expressed as mM Leucine equivalents.
- The extent of the proteolysis in the enzymatic hydrolysed and/or fermented casein products is presented as degree of hydrolysis (DH), which is defined as follows:
-
Degree of hydrolysis=number of peptide bonds cleaved/total number of peptide bonds present in protein*100% - Skimmed milk (9% SMP) was reconstituted by mixing 9 wt % skim milk powder (Promex, ex Coberco, Netherlands) in tap water and sterilised. The sterile reconstituted skim milk was incubated at 50° C. for 6 hours at pH 7.0 with either 0.16 wt % (5 wt % based on casein) Fungal Protease Concentrate (ex Genencor) or 0.16 wt % (5 wt % based on casein) Umamizyme (ex Amano). Both enzyme mixtures are derived from Aspergillus oryzae, and are comprised of proteinases and peptidases.
- A casein starting material was fermented with Lactobacillus helveticus CNRZ 244 and the resulting fermented milk herein also designated as fermented milk substrate was treated with enzymes mentioned in table 1.
- Preparation of the Fermented Milk Substrate:
- Sterile skim milk (Yopper ex Campina, Netherlands) was inoculated for 24 hours at 37° C. with 4% of a culture of a Lactobacillus helveticus CNRZ 244 that had been stored at −80° C. as a full grown culture in the above described skim milk, diluted with sterile 10% glycerol to an end concentration of 6% glycerol. This preculture was designated as preculture-1
- A preculture (preculture-2) was prepared with sterile skim milk (Yopper, ex Campina, Netherlands), which was inoculated with 2 wt % preculture-1 of Lactobacillus helveticus CNRZ 244. Preculture-2 was stirred and incubated at 40° C. for 24 hours under anaerobic conditions, using a headspace nitrogen gas flush.
- Skimmed milk was reconstituted by mixing 9 wt % skim milk powder (Promex, ex Coberco, Netherlands) in tap water and sterilised. The sterile reconstituted milk was inoculated with 2 wt % of preculture-2 in a stirred tank reactor. Stirred speed was maintained at 150 rpm and dissolved oxygen and pH were monitored.
- Anaerobic conditions were maintained using a headspace flush with nitrogen gas. During the first 8 hours of fermentation the pH of the milk was allowed to decrease from pH 6.5 to pH 4.6. At pH 4.6 the pH was controlled for 3.5 hours, using a base mixture of calciumhydroxide and potassiumhydroxide. After this pH controlled phase the pH was again allowed to decrease to 4.0.
- After fermentation the fermented milk was pasteurised for 15 seconds at 75° C. The pasteurised fermented milk product is designated as fermented milk substrate in comparative example A.
- For examples 3-6 and comparative examples B-I the fermented milk substrate was incubated with 0.16 wt % (5 wt % based on casein) of the various enzyme mixtures comprising of proteinases and peptidases at 50° C. for six hours at pH 7.
-
TABLE 1 Enzyme mixtures (protease and peptidase mixtures) used in examples 1-5 and comparative experiments A-K, and their activities measured in the crude enzyme mixtures. X-prolyl Example/ dipeptidyl Comparative Proteolytic amino peptidase Experiment Enzyme Derived from: Supplier activity (U/kg) activity (U/kg) 1 Fungal Aspergillus Genencor 1219 730 protease oryzae Concentrate 2 Umamizyme Aspergillus Amano 2112 2768 oryzae A NA Lb. helveticus NA NA NA Fermentation B Proleather Bacillus subtilis Amano 2618 107 FG-F C Multifect Bacillus subtilis Genencor 2547 23 P-3000 D Multifect Bacillus 1603 26 Neutral amyloliquefaciens E Peptidase R Rhizopus oryzae Amano ND ND F Protex 6L Bacillus Genencor 4287 13 licheniformis G Promod 280P Bacillus subtilis Biocatalyst ND ND H Pepsin Hog stomach Biocatalyst BDL 0 P389P I GC 106 Aspergillus niger Geneneor BDL 13 3 Promod 194P Aspergillus Biocatalyst 1025 483 4 Fungal Aspergillus Genencor 1219 730 protease oryzae concentrate 5 Umamizyme Aspergillus Amano 2112 2768 oryzae K Flavourzyme Aspergillus Novozymes 357 117 oryzae (ND = not determined, NA = not applicable, BDL = below detection limit) -
TABLE 2 Results of incubation experiments with protease and peptidase mixtures in examples 1-5 and comparative examples A-I (ND is Not determined; NA is Not applicable): Molar Molar Yield Molar Yield IPP on Yield VPP Beta- LPP Degree Conc Conc Conc Conc on & on of IPPL VPP IPP LPP IPPeq BPPeq beta- Kappa Beta- Hydrolysis Ex Substrate (μM) (μM) (μM) (μM) (μM) (μM) casein Casein casein DH 1 9% SMP 2 293 331 207 493 601 67% 53% 47% 39% 2 9% SMP 0 350 413 367 608 799 80% 66% 84% 55% A 9% SMP 23 96 83 0 136 136 22% 13% 0% ND B Fermented 13 49 40 0 67 67 11% 6% 0% 19% milk C Fermented 13 56 40 0 71 71 13% 6% 0% 14% milk D Fermented 33 44 58 0 82 82 10% 9% 0% 19% milk E Fermented 25 45 62 0 87 87 10% 10% 0% 23% milk F Fermented 14 89 38 0 87 87 20% 6% 0% 15% milk G Fermented 17 81 76 0 121 121 19% 12% 0% 6% milk H Fermented 26 91 85 0 135 135 21% 13% 0% 3% milk I Fermented 0 90 87 54 137 165 21% 14% 12% 3% milk 3 Fermented 3 88 99 88 148 194 20% 16% 20% 28% milk 4 Fermented 0 427 421 285 658 807 98% 67% 65% 37% milk 5 Fermented 0 320 354 375 532 727 73% 56% 86% 52% milk - Results from examples 1-5 show both milk and fermented milk incubated with enzyme mixtures derived from Aspergillus and more in particular Aspergillus oryzae give rise to high IPP, LPP and VPP levels.
- The molar yield of LPP on beta-casein was found to be higher than 20% in examples 1 to 5.
- Examples 1, 2, 4 and 5 all show high levels of IPP, VPP and LPP and thus high corresponding IPPeq and BPPeq values were determined. In these examples the enzyme was derived from Aspergillus Oryzae.
- Example 2 shows high levels of IPP, LPP and VPP can be obtained by incubation reconstituted milk with Umamizyme (ex Amano). Furthermore high molar yields of VPP and LPP of 80% and 84% respectively were found in example 2.
- A near to complete release of all the VPP present in the beta-casein—indicated by the 98% molar yield—could be shown after the incubation of fermented milk with Fungal protease concentrate (ex Genencor) in example 4.
- The high values for total proteolysis in examples 1, 2, 4 and 5 correspond to a high degree of hydrolysis of 37 to 55% of the milk proteins.
- In examples 1-5 very low or no presence of IPPL was found. During these incubations most of the IPPL formed therefore converted into IPP.
- The comparative examples B-H showed a decrease in concentration of the bio-active peptides IPP and VPP after incubation with the proteinase and peptidase mixtures, compared to the concentrations present in the fermented milk substrate (example A). No formation of LPP could be shown in these comparative examples B to H.
- The hydrolysed casein products obtained according to examples 1 and 4 were used to produce milk and fermented milk drinks.
- The milk drinks contained 12.5 wt % of hydrolysed casein products in pasteurised skim milk and the following ingredients: 4.5 wt % sucrose (ex CSM, Netherlands), 1 wt % fructose syrup (ex Sensus, Netherlands), 2 wt % Multifruit fruitpulp (ex Wild, Netherlands), 0.1 wt % yoghurt flavour ZD-49492 (ex Quest, Netherlands), 0.03 wt % fruit flavour 037-00330-11 (ex Givaudan, Switzerland), 0.1 wt % cream flavour U33162 (ex Danisco, Denmark) and 0.8 wt. % Genu pectine YM-115-H (ex CP Kelco, Denmark).
- After the ingredients were mixed in, the milk drinks were homogenised at 150 bar and pasteurised for 15 seconds at 75° C.
- The taste of the milk drinks was good. No bitterness was noticed.
- The hydrolysed casein solids was prepared as described herein:
- A reactor was filled with 10 wt % calcium caseinate (ex DMV, Netherlands), pasteurised at 85° C. for 20 minutes, cooled to 50° C. and incubated under anaerobic conditions with 0.5% wt Umamizyme (ex Amano) for 6 hours at 50° C.
- After incubation the pH of the hydrolysate was adjusted from pH 6.2 to pH 4 using 80% wt lactic acid (ex Purac, Netherlands) and the remaining enzymes were deactivated by heating the hydrolysate at 95° C. for 20 minutes. Prior to freeze drying the hydrolysate was stored at −20° C.
- After freeze drying the content of the tripeptides VPP, IPP and LPP were analysed by HPLC-MRM-MS as described before. The hydrolysed casein solids contained:
- 1677.2 μg/g VPP; 2664.6 μg/g IPP and 2019.5 μg/g LPP (averaged values from six measurements).
- The yoghurt drink contained 60 wt % low fat yoghurt (ex Melkan, Netherlands); 9 wt % sucrose (ex CSM, Netherlands); 0.35 wt % AMD 783 pectine (ex Danisco, Denmark); 1.23 wt % hydrolysed casein solids; 0.025 wt % raspberry 502824 A (ex Firmenich, Switserland) and 29.4 wt % demineralised water.
- After all ingredients were mixed into the yoghurt the yoghurt drink was homogenised at 150 bar and pasteurised for 15 seconds at 75° C.
- The final VPP, IPP and LPP content of the yoghurt drink was 66 μM, 100 μM and 76 μM respectively. The taste of the yoghurt drink containing 1.23 wt % hydrolysed casein solids was good and no bitter taste was noticed.
- The 3.2 wt %; 6 wt % and 10 wt % casein substrates were prepared by mixing in appropriate levels of calcium caseinate (ex DMV, Netherlands) in tap water. A high skim milk (18% SMP) substrate was prepared by mixing 18 wt % skim milk powder (ex Coberco, Netherlands) in tap water. All substrates, 18% SMP and the casein substrates were incubated at 50° C. for six hours. Prior to these incubations the pH was adjusted to pH 7.0. All substrates were incubated with Umamizyme (ex Amano), the ratio enzyme mixture to casein was 5 wt %.
-
TABLE 3 Results of the incubation experiments using Umamizyme at different levels of casein and skim milk powder in examples 9-12. Molar yield Molar IPP Molar yield on yield VPP beta- LPP Degree Conc Conc Conc on & on of VPP IPP LPP IPPeq BPPeq beta- kappa beta- Hydrolysis Ex. Substrate (μM) (μM) (μM) (μM) (μM) casein casein casein DH 9 3.2% 294 417 343 580 758 67% 66% 78% 59% casein 10 6.0% 473 732 566 995 1289 58% 62% 69% 55% casein 11 10.0% 703 1000 794 1391 1804 51% 51% 58% 57% casein 12 18% 541 628 522 929 1201 62% 50% 60% 46% SMP - Results from examples 9, 10 and 11 clearly show increased amounts of casein substrate lead to higher levels of the bio-active peptides VPP, IPP and LPP and to very high corresponding IPPeq and BPPeq values. With increasing casein substrate levels the molar yields of VPP, IPP and LPP on casein decreased although the resulting molar yields at the highest level of casein substrate (10 wt %) are still above 50%.
- The substrate used in these incubations contained 10 wt % casein and was prepared by mixing an appropriate level of calcium caseinate (ex DMV, Netherlands) in tap water. The incubation was performed at 50° C. for six hours and prior to these incubations the pH was not adjusted. All incubation were performed using the Umamizyme (ex Amano) enzyme mixture, the ratio enzyme mixture to casein used were 1 wt %; 2.5 wt %; 4 wt % and 5 wt %.
-
TABLE 4 Results of the incubation experiments using different enzyme/substrate ratios in examples 13-15 and comparative example J. Molar Molar yield Molar yield IPP yield VPP on LPP Degree Enzyme/ Conc Conc Conc on beta- & on of Substrate VPP IPP LPP IPPeq BPPeq beta- kappa beta- hydrolysis Ex. Ratio (μM) (μM) (μM) (μM) (μM) casein casein casein DH J 1.0% 84 166 72 213 250 6% 8% 5% 29% 13 2.5% 398 730 543 951 1234 29% 37% 40% 42% 14 4.0% 727 1005 810 1409 1831 53% 51% 59% 47% 15 5.0% 986 983 814 1531 1955 72% 50% 59% 52% - Results from example 13-15 and comparative example J indicate an enzyme to substrate ratio over 1% is needed to obtain high yields of VPP, IPP and LPP on the casein substrate.
- Again very high levels of VPP, IPP and LPP were obtained. In example 15 the highest levels VPP, IPP and LPP were obtained corresponding to an IPPeq value of 1531 μM and a BPPeq value of 1955 μM.
- Comparative example K was executed according to example 15 with an enzyme to substrate ratio of 5% based on casein, except in this case a different enzyme mixture is used. A 10% casein solution was incubated using Flavourzyme (ex Novozymes) instead of Umamizyme (ex Amano). After the incubation the bioactive peptide VPP and the degree of hydrolysis were determined. Some characteristics of the Flavourzyme enzyme mixture are shown in Table 1.
-
TABLE 5 Results incubation experiment of 10% casein using Flavourzyme Molar yield Enzyme/ Conc VPP on Degree Of Substrate VPP beta- Hydrolysis Example Substrate ratio (μM) casein DH K 10% casein 5% 16 1% 45% - Results indicate besides a high proteolytic activity a relatively high X-prolyl dipeptidyl amino peptidase activity is needed to obtain high levels of the active tripeptide VPP.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/836,876 US20110142989A1 (en) | 2003-05-05 | 2010-07-15 | Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03076307 | 2003-05-05 | ||
EP03076307.2 | 2003-05-05 | ||
PCT/EP2004/004385 WO2004098309A1 (en) | 2003-05-05 | 2004-04-23 | Hydrolysed casein product comprising tripeptides ipp and/ or vpp |
US55563305A | 2005-11-04 | 2005-11-04 | |
US12/836,876 US20110142989A1 (en) | 2003-05-05 | 2010-07-15 | Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/004385 Division WO2004098309A1 (en) | 2003-05-05 | 2004-04-23 | Hydrolysed casein product comprising tripeptides ipp and/ or vpp |
US55563305A Division | 2003-05-05 | 2005-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110142989A1 true US20110142989A1 (en) | 2011-06-16 |
Family
ID=33427136
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/555,633 Expired - Fee Related US7785824B2 (en) | 2003-05-05 | 2004-04-23 | Hydrolysed casein product comprising tripeptides IPP and/or VPP |
US12/836,876 Abandoned US20110142989A1 (en) | 2003-05-05 | 2010-07-15 | Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/555,633 Expired - Fee Related US7785824B2 (en) | 2003-05-05 | 2004-04-23 | Hydrolysed casein product comprising tripeptides IPP and/or VPP |
Country Status (11)
Country | Link |
---|---|
US (2) | US7785824B2 (en) |
EP (1) | EP1619957A1 (en) |
JP (1) | JP2006525003A (en) |
CN (1) | CN1784145A (en) |
AR (1) | AR044251A1 (en) |
AU (1) | AU2004237455B2 (en) |
BR (1) | BRPI0409536A (en) |
CA (1) | CA2523410A1 (en) |
MX (1) | MXPA05011784A (en) |
WO (1) | WO2004098309A1 (en) |
ZA (1) | ZA200507880B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207944A1 (en) * | 2004-07-12 | 2007-09-06 | Luppo Edens | Blood Pressure Lowering Oligopeptides |
GB2421890A (en) * | 2004-12-09 | 2006-07-12 | Biocatalysts Ltd | Method for producing a palatability enhancer for a foodstuff |
CN101084004A (en) * | 2004-12-22 | 2007-12-05 | 帝斯曼知识产权资产管理有限公司 | Blood pressure lowering peptides in a single enzymatic step |
KR101244995B1 (en) * | 2005-02-24 | 2013-03-18 | 디에스엠 아이피 어셋츠 비.브이. | Blood pressure lowering peptides from glycomacropeptide |
JP2006254791A (en) * | 2005-03-17 | 2006-09-28 | Morinaga Milk Ind Co Ltd | Casein hydrolysate-containing composition |
EP1874129A1 (en) * | 2005-04-28 | 2008-01-09 | Unilever PLC | Peptides having an ace inhibiting effect |
US20090304869A1 (en) * | 2005-04-28 | 2009-12-10 | Christianus Jacobus Van Platerink | Peptides Having an Ace Inhibiting Effect |
EP1908354A4 (en) * | 2005-07-26 | 2011-12-28 | Calpis Co Ltd | Process for production of fermented milk and fermented milk beverage/food |
US20100167979A1 (en) | 2006-02-09 | 2010-07-01 | Calpis Co. Ltd | Rheumatoid arthritis-preventive agent for oral intake |
CA2642539C (en) * | 2006-02-14 | 2013-01-08 | Calpis Co., Ltd. | Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function |
DE202006015338U1 (en) * | 2006-09-14 | 2007-04-12 | Soba Biotec Gmbh | Use of proteases to produce hydrolyzed mare's milk or hydrolyzed mare's milk powder useful as or in foods, dietary supplements, medicaments or cosmetic products |
JP2008125380A (en) * | 2006-11-17 | 2008-06-05 | Marukome Kk | Method for producing functional fermented soybean paste |
US20090298773A1 (en) * | 2006-11-17 | 2009-12-03 | Marukome Co., Ltd. | Methods of producing functional miso |
CN101678071A (en) | 2007-03-27 | 2010-03-24 | 卡尔皮斯株式会社 | Prophylactic agent for renal failure |
EP2222835A1 (en) * | 2007-11-23 | 2010-09-01 | DSM IP Assets B.V. | Improved bioactive peptide production |
CN102014947B (en) * | 2008-03-26 | 2016-10-19 | 格兰比亚营养物(爱尔兰)有限公司 | Rich in leucic peptide combinations and separation method |
EP2303030A1 (en) * | 2008-06-12 | 2011-04-06 | Nestec S.A. | Lactobacillus helveticus strains for producing hypotensive peptides |
US20120028902A1 (en) * | 2008-10-21 | 2012-02-02 | Kies Arie K | Peptide availability |
EP2352394A2 (en) * | 2008-10-21 | 2011-08-10 | DSM IP Assets B.V. | Improved peptide availability |
CN101824453A (en) * | 2009-03-05 | 2010-09-08 | 东北农业大学 | Two-stage preparation technology of high activity casein antioxidant peptides |
FI122531B (en) * | 2009-09-30 | 2012-03-15 | Valio Oy | Cheese and process for making them |
EP2533791B1 (en) * | 2009-12-21 | 2017-01-25 | Glanbia Nutritionals (Ireland) Ltd. | Leucine/peptide composition and method of formulation |
US9523109B2 (en) * | 2011-06-24 | 2016-12-20 | Calpis Co., Ltd. | Method for enzymatically preparing peptides for use in improvement of brain function |
CN102771557B (en) * | 2012-08-10 | 2014-01-08 | 光明乳业股份有限公司 | Beverage containing functional hydrolyzed protein peptide milk and preparation method thereof |
CN102948476A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Method for preparing goat milk beverage containing ACE (Angiotensin Converting Enzyme) inhibitory peptide on basis of fermentation of Lactobacillus helveticus |
CN102960444A (en) * | 2012-11-19 | 2013-03-13 | 陕西科技大学 | Preparation method of goat milk containing ACE (Angiotensin Converting Enzyme) inhibitory peptide based on Lactobacillus helveticus fermentation |
US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
CN103211024A (en) * | 2013-04-16 | 2013-07-24 | 陕西科技大学 | Method for preparing goat milk beverage containing ACE (Angiotensin Converting Enzyme) inhibitory peptide |
CN111909978B (en) * | 2020-07-10 | 2021-06-22 | 青岛农业大学 | Method for directionally preparing hydrolysate rich in LPP from corn protein powder by using fermentation method |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10212245A (en) * | 1998-01-23 | 1998-08-11 | Agency Of Ind Science & Technol | Inhibitor preparation of angiotensin converting enzyme |
WO2001032905A1 (en) * | 1999-11-01 | 2001-05-10 | Valio Ltd | Process for producing a product containing antihypertensive tripeptides |
EP1201679A2 (en) * | 2000-10-27 | 2002-05-02 | Riken Vitamin Co., Ltd. | Angiotensin I-converting enzyme inhibitory substance |
KR20030003462A (en) * | 2001-07-02 | 2003-01-10 | 대한민국(관리부서:농촌진흥청) | Antihypertensive casein protein hydrolysate and manufacturing method thereof |
US6994987B1 (en) * | 1999-11-11 | 2006-02-07 | Calpis Co., Ltd. | Process for producing tripeptides |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2805032B2 (en) * | 1988-07-27 | 1998-09-30 | 工業技術院長 | Angiotensin converting enzyme inhibitor |
DK46793D0 (en) * | 1993-04-26 | 1993-04-26 | Novo Nordisk As | ENZYME |
AU695395B2 (en) * | 1994-10-26 | 1998-08-13 | Novozymes A/S | Method for production of a milk protein hydrolyzate, the milk protein hydrolyzate and use of the milk protein hydrolyzate |
JP3028411B2 (en) | 1997-09-26 | 2000-04-04 | カルピス株式会社 | Lactobacillus helveticus lactic acid bacteria with high tripeptide productivity |
JP4727770B2 (en) * | 1997-09-26 | 2011-07-20 | カルピス株式会社 | At least one alleviating agent for lowering urinary catecholamine, lowering urinary noradrenaline, lowering urinary dopamine and lowering Fischer ratio |
AU2003296605B2 (en) | 2003-01-06 | 2007-06-28 | Unilever Plc | Fermented milk product comprising tripeptide VPP and/or IPP |
US20070207944A1 (en) | 2004-07-12 | 2007-09-06 | Luppo Edens | Blood Pressure Lowering Oligopeptides |
CN101084004A (en) | 2004-12-22 | 2007-12-05 | 帝斯曼知识产权资产管理有限公司 | Blood pressure lowering peptides in a single enzymatic step |
ATE425671T1 (en) | 2005-02-09 | 2009-04-15 | Unilever Nv | FOOD PRODUCTS WITH HYDROLYZED MILK SOLIDS WITH IMPROVED FLAVOR |
KR101244995B1 (en) | 2005-02-24 | 2013-03-18 | 디에스엠 아이피 어셋츠 비.브이. | Blood pressure lowering peptides from glycomacropeptide |
US20090042809A1 (en) | 2005-04-28 | 2009-02-12 | Luppo Edens | Blood Pressure Lowering Protein Hydrolysates |
JP2008539203A (en) | 2005-04-28 | 2008-11-13 | ディーエスエム アイピー アセッツ ビー.ブイ. | New nutritional supplement composition |
EP1874129A1 (en) | 2005-04-28 | 2008-01-09 | Unilever PLC | Peptides having an ace inhibiting effect |
BRPI0612183A2 (en) | 2005-04-28 | 2010-10-26 | Unilever Nv | methionine-alanine-proline and / or isoleucine-threonine-proline or their salts, their uses, methods of treatment, medicament, dietary supplement, food, compositions, processes of production of isoleucine-threonine-proline or its salt, of methionine production -alanine proline or its salt and methionine-alanine-proline and / or isoleucine-threonine-proline production |
EP1874140B1 (en) | 2005-04-28 | 2011-02-09 | Unilever N.V. | Peptides having a health benefit and compositions comprising them |
US20090304869A1 (en) | 2005-04-28 | 2009-12-10 | Christianus Jacobus Van Platerink | Peptides Having an Ace Inhibiting Effect |
-
2004
- 2004-04-23 CA CA002523410A patent/CA2523410A1/en not_active Abandoned
- 2004-04-23 AU AU2004237455A patent/AU2004237455B2/en not_active Ceased
- 2004-04-23 WO PCT/EP2004/004385 patent/WO2004098309A1/en active IP Right Grant
- 2004-04-23 CN CNA2004800118544A patent/CN1784145A/en active Pending
- 2004-04-23 JP JP2006505269A patent/JP2006525003A/en active Pending
- 2004-04-23 US US10/555,633 patent/US7785824B2/en not_active Expired - Fee Related
- 2004-04-23 BR BRPI0409536-7A patent/BRPI0409536A/en not_active IP Right Cessation
- 2004-04-23 MX MXPA05011784A patent/MXPA05011784A/en not_active Application Discontinuation
- 2004-04-23 EP EP04729084A patent/EP1619957A1/en not_active Ceased
- 2004-04-23 ZA ZA200507880A patent/ZA200507880B/en unknown
- 2004-05-05 AR ARP040101529A patent/AR044251A1/en unknown
-
2010
- 2010-07-15 US US12/836,876 patent/US20110142989A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10212245A (en) * | 1998-01-23 | 1998-08-11 | Agency Of Ind Science & Technol | Inhibitor preparation of angiotensin converting enzyme |
WO2001032905A1 (en) * | 1999-11-01 | 2001-05-10 | Valio Ltd | Process for producing a product containing antihypertensive tripeptides |
US6994987B1 (en) * | 1999-11-11 | 2006-02-07 | Calpis Co., Ltd. | Process for producing tripeptides |
EP1201679A2 (en) * | 2000-10-27 | 2002-05-02 | Riken Vitamin Co., Ltd. | Angiotensin I-converting enzyme inhibitory substance |
KR20030003462A (en) * | 2001-07-02 | 2003-01-10 | 대한민국(관리부서:농촌진흥청) | Antihypertensive casein protein hydrolysate and manufacturing method thereof |
Non-Patent Citations (4)
Title |
---|
Greenberg, R., et al "Human b-Casein: Amino Acid Identification of Phosphorylation Sites" The Journal of Biological Chemistry. 1984, 259(8), 5132-5138. * |
Kohmura et al (1990) Agric. Biochem. Chem., 54, pp.835-836 * |
Maruyama et al (1989), Agricultural and Biochemical Chemistry, 53, 1077-1081. * |
Nakamura et al. (1995) J. Dalry Sci. 78, 1253-1257. * |
Also Published As
Publication number | Publication date |
---|---|
ZA200507880B (en) | 2006-12-27 |
WO2004098309A1 (en) | 2004-11-18 |
JP2006525003A (en) | 2006-11-09 |
CN1784145A (en) | 2006-06-07 |
AR044251A1 (en) | 2005-09-07 |
AU2004237455A1 (en) | 2004-11-18 |
MXPA05011784A (en) | 2006-01-26 |
BRPI0409536A (en) | 2006-04-18 |
AU2004237455B2 (en) | 2007-08-02 |
US7785824B2 (en) | 2010-08-31 |
US20070054352A1 (en) | 2007-03-08 |
CA2523410A1 (en) | 2004-11-18 |
EP1619957A1 (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7785824B2 (en) | Hydrolysed casein product comprising tripeptides IPP and/or VPP | |
ZA200504572B (en) | Fremented milk product comprising tripeptide VPP and/or IPP | |
EP1226267B1 (en) | Process for producing a product containing antihypertensive tripeptides | |
EP1907412B1 (en) | Peptides inhibiting angiotensin-converting enzyme | |
AU761477B2 (en) | Bioactive whey protein hydrolysate | |
US20110045130A1 (en) | Bioactive peptide production | |
US20020182301A1 (en) | Fermented milk product | |
JP2004508025A (en) | Improved bioactive whey protein hydrolyzate | |
Wang et al. | Fermentation characteristics and angiotensin I-converting enzyme–inhibitory activity of Lactobacillus helveticus isolate H9 in cow milk, soy milk, and mare milk | |
Shori et al. | Fermented milk derives bioactive peptides with antihypertensive effects | |
US20060216330A1 (en) | Peptides having an ace inhibiting effect | |
Kilara et al. | Enzyme‐modified dairy ingredients | |
US20070141120A1 (en) | Peptide having an ace inhibiting effect | |
AU2003204321B2 (en) | Bioactive Whey Protein Hydrolysate | |
KR20070009626A (en) | Method of preparing a food ingredient and food product having angiotensin-i-converting enzyme inhibiting properties and products thus obtained | |
MXPA06006596A (en) | Peptides having an ace inhibiting effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UNILEVER N.V.;UNILEVER PLC;REEL/FRAME:028217/0676 Effective date: 20110728 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND APPLICATION NUMBER PREVIOUSLY RECORDED ON REEL 028217 FRAME 0676. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:UNILEVER N.V.;UNILEVER PLC;REEL/FRAME:031160/0501 Effective date: 20110728 |